Candel Therapeutics
CADL
23 hedge funds and large institutions have $20.6M invested in Candel Therapeutics in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 23 → 23 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
1.14% less ownership
Funds ownership: 23.26% → 22.12% (-1.1%)
39% less capital invested
Capital invested by funds: $34M → $20.6M (-$13.4M)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.98M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$231K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$7.24K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.67K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$4.12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.3M |
| 2 |
6CM
683 Capital Management
New York
|
-$208K |
| 3 |
D.E. Shaw & Co
New York
|
-$55K |
| 4 |
BlackRock
New York
|
-$11.8K |
| 5 |
JP Morgan Chase
New York
|
-$8.57K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| – | +$244 | +61 | New |
|
CADL Hedge Fund Activity: Q2 2022 in Review
23 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q2 2022, worth a combined $20.6M — down 39% from $34M a quarter earlier.
Fund positioning in CADL was balanced in Q2 2022: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 8 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $2.98M. The largest seller was Fidelity Investments, cutting an estimated $4.3M.
- 23 institutional investors held Candel Therapeutics (CADL) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $20.6M of Candel Therapeutics stock for Q2 2022, down 39% quarter-over-quarter.
- 3 funds opened new Candel Therapeutics positions in Q2 2022 and 3 closed out, a net change of 0 holders.
- The largest Candel Therapeutics buyer in Q2 2022 was Point72 Asset Management, an estimated $2.98M added.
- The largest Candel Therapeutics seller in Q2 2022 was Fidelity Investments, an estimated $4.3M sold.
Based on aggregated 13F filings for Q2 2022.